{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/51376"},"canonical_url":"https://search.ndltd.org/etd/bu/oai:open.bu.edu:2144/51376","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Preventing CVD: treatment of elevated lipoprotein(a) with respect to LPA gene isoform type","abstract":"Lipoprotein(a) [Lp(a)] is a unique low density lipoprotein consisting of an apolipoprotein(a) and apolipoprotein B subunit that is an established genetic risk factor for atherosclerotic cardiovascular disease (ASCVD). Current therapeutic options for inherited elevated circulating Lp(a) are generally limited to off-target effects of other cardiovascular therapies, making treatment for this condition difficult. This work evaluates a variety of established cardiovascular treatments and their impact on Lp(a) plasma concentration while taking into consideration potential impacts of Lp(a) isoform types on treatment response. It also assesses the value of Lp(a) lowering therapies based on their relative cardioprotective benefit, lowering or preventing occurrences of major adverse cardiovascular events (MACE) and ASCVD.","abstract_html":"Lipoprotein(a) [Lp(a)] is a unique low density lipoprotein consisting of an apolipoprotein(a) and apolipoprotein B subunit that is an established genetic risk factor for atherosclerotic cardiovascular disease (ASCVD). Current therapeutic options for inherited elevated circulating Lp(a) are generally limited to off-target effects of other cardiovascular therapies, making treatment for this condition difficult. This work evaluates a variety of established cardiovascular treatments and their impact on Lp(a) plasma concentration while taking into consideration potential impacts of Lp(a) isoform types on treatment response. It also assesses the value of Lp(a) lowering therapies based on their relative cardioprotective benefit, lowering or preventing occurrences of major adverse cardiovascular events (MACE) and ASCVD.","abstract_has_math":false,"creators":["Brooks, Alexis"],"institution":"Boston University","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Medical Sciences","degree_department":null,"school":null,"contributors":[],"advisors":["Moreira-Bouchard, Jesse","Gerstenfeld, Louis"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024","date_published":"2024","updated_at":"2026-11-18T19:50:36Z","subjects":["Genetics","Medicine","ASCVD","Cardiovascular disease","Isoform","Lipoprotein(a)","Lp(a)","PCSK9"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[{"key":"dc:identifier.orcid","label":"ORCID","values":["0009-0007-2005-9818"],"render_values":[{"text":"0009-0007-2005-9818","href":"https://orcid.org/0009-0007-2005-9818","code":true}]}]},"links":{"outbound_url":"https://hdl.handle.net/2144/51376","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/2144/51376","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://open.bu.edu/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aopen.bu.edu%3A2144%2F51376","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Moreira-Bouchard, Jesse","Gerstenfeld, Louis"]},{"key":"dc:creator","label":"Author","values":["Brooks, Alexis"]},{"key":"dc:identifier.orcid","label":"ORCID","values":["0009-0007-2005-9818"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-09-30T14:57:38Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-09-30T14:57:38Z"]},{"key":"dc:date.issued","label":"Date","values":["2024"]},{"key":"dc:date.updated","label":"Dc Date Updated","values":["2025-09-23T19:08:42Z"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Medical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Boston University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Genetics","Medicine","ASCVD","Cardiovascular disease","Isoform","Lipoprotein(a)","Lp(a)","PCSK9"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/51376"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["2024"]},{"key":"dc:description.abstract","label":"Abstract","values":["Lipoprotein(a) [Lp(a)] is a unique low density lipoprotein consisting of an apolipoprotein(a) and apolipoprotein B subunit that is an established genetic risk factor for atherosclerotic cardiovascular disease (ASCVD). Current therapeutic options for inherited elevated circulating Lp(a) are generally limited to off-target effects of other cardiovascular therapies, making treatment for this condition difficult. This work evaluates a variety of established cardiovascular treatments and their impact on Lp(a) plasma concentration while taking into consideration potential impacts of Lp(a) isoform types on treatment response. It also assesses the value of Lp(a) lowering therapies based on their relative cardioprotective benefit, lowering or preventing occurrences of major adverse cardiovascular events (MACE) and ASCVD."]},{"key":"dc:title","label":"Title","values":["Preventing CVD: treatment of elevated lipoprotein(a) with respect to LPA gene isoform type"]}]}],"canonical_facts":{"dc:contributor.advisor":["Moreira-Bouchard, Jesse","Gerstenfeld, Louis"],"dc:creator":["Brooks, Alexis"],"dc:date.accessioned":["2025-09-30T14:57:38Z"],"dc:date.available":["2025-09-30T14:57:38Z"],"dc:date.issued":["2024"],"dc:date.updated":["2025-09-23T19:08:42Z"],"dc:description":["2024"],"dc:description.abstract":["Lipoprotein(a) [Lp(a)] is a unique low density lipoprotein consisting of an apolipoprotein(a) and apolipoprotein B subunit that is an established genetic risk factor for atherosclerotic cardiovascular disease (ASCVD). Current therapeutic options for inherited elevated circulating Lp(a) are generally limited to off-target effects of other cardiovascular therapies, making treatment for this condition difficult. This work evaluates a variety of established cardiovascular treatments and their impact on Lp(a) plasma concentration while taking into consideration potential impacts of Lp(a) isoform types on treatment response. It also assesses the value of Lp(a) lowering therapies based on their relative cardioprotective benefit, lowering or preventing occurrences of major adverse cardiovascular events (MACE) and ASCVD."],"dc:identifier.orcid":["0009-0007-2005-9818"],"dc:identifier.uri":["https://hdl.handle.net/2144/51376"],"dc:language.iso":["en_US"],"dc:subject":["Genetics","Medicine","ASCVD","Cardiovascular disease","Isoform","Lipoprotein(a)","Lp(a)","PCSK9"],"dc:title":["Preventing CVD: treatment of elevated lipoprotein(a) with respect to LPA gene isoform type"],"dc:type":["Thesis/Dissertation"],"thesis:degree_discipline":["Medical Sciences"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Boston University"]},"updated_at":"2026-11-18T19:50:36Z"}